Add like
Add dislike
Add to saved papers

Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.

INTRODUCTION: Individual prediction of local recurrence (LR) risk after breast-conserving surgery (BCS) for ductal carcinoma-in-situ (DCIS) is needed to identify women at low risk, for whom radiotherapy may be omitted. PATIENTS AND METHODS: Three predictive models of LR-clinicopathologic factors (CPF) alone; CPF + estrogen receptor (ER) + human epidermal growth factor receptor 2 (HER2); and CPF + DCIS score (DS)-were developed among 1102 cases of DCIS in patients with complete covariate and outcome data. Categorizations of discrete variables and transformations of continuous variables were examined in Cox models; 2-way interactions and interactions with time were assessed. Internal validation was performed by bootstrapping. Individual predicted 10-year LR risks were computed from covariate values, estimated regression parameters, and estimated baseline survival function. Accuracy was assessed by c statistics and calibration plots.

RESULTS: The strongest prediction model incorporated CPF + DS. The c statistics for CPF + DS, CPF + ER + HER2, or CPF-alone models were 0.7025, 0.6879, and 0.6825, respectively. The CPF + DS model was better calibrated at predicting low (≤ 10%) individual 10-year LR risks after BCS alone than those incorporating CPF + ER + HER2 or CPF alone, evidenced by c statistics and plots of observed by predicted risks. Among women aged ≥ 50 with no adverse CPF, the CPF + DS model identified the greatest proportion of women (62.3%) with predicted individual 10-year LR ≤ 10% without radiotherapy compared to the CPF + ER + HER2 (50.9%) or CPF alone (46.5%) models.

CONCLUSION: Individual prediction of LR incorporating DS is more accurate and identifies a higher proportion of women with low predicted risk of LR after BCS alone, for whom radiotherapy may be omitted.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app